Drug intelligence / Profile preview

CMOEP

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

CMOEP is a combination chemotherapy regimen used in the treatment of untreated peripheral T-cell lymphoma. The acronym "CMOEP" refers to a multi-agent protocol, but the specific components are not fully detailed in the available sources. However, based on standard oncology naming conventions and partial information from clinical trial records, it likely includes cyclophosphamide and mitoxantrone hydrochloride as key agents[1]. The regimen is designed to target malignant lymphocytes through multiple mechanisms of action associated with its constituent drugs.

Other names: CMOEP regimen

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on CMOEP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMOEP.

Explore the full profile